Bowel cleansing products comparison chart (hyperosmotics, isosmotics, isosmotic/stimulant laxative combinations, osmotics) used for colonoscopy preparation.
NSAIDs target stem cells that have accumulated mutations that could lead to cancer development and a biochemical pathway that leads to apoptosis.
Reasons behind rise in colorectal cancer unclear, and it's happening even as rates decline among older Americans.
Fecal immunochemical testing may be as effective as colonoscopies in being able to detect colorectal cancer risk.
The new test is more sensitive than fecal occult blood tests but carries a higher risk of false-positives.
Changes to Medicaid reimbursements can improve cancer screening rates.
Second study shows no benefit from CRC screening more intensively than recommended.
The FDA has appproved Cologuard, the first non-invasive DNA screening test for colorectal cancer.
Narrow band imaging may improve visualization of polyps during colonoscopy, but there are still questions as to whether it is a truly useful screening tool.
A fact sheet to review the different types of test used to detect colon cancer and polyps.
Multifaceted intervention relied upon letters, telephone calls, and text messages.
Patients cared for by doctors who removed more adenomas were less likely to develop colon cancer.
Colorectal cancer screening should be considered in unscreened patients older than 75 years.
New colorectal cancer surveillance strategies are warranted in cervical cancer survivors who have been treated with radiotherapy.
For patients undergoing colonoscopy, L-menthol sprayed directly onto the colonic mucosa improves the adenoma detection rate.
A considerable number of women testing negative for BRCA1/2 may have pathogenic mutations in other genes.
Diagnosing and treating a cancer of unknown origin can be a challenging and daunting task for clinicians.
Six percent of patients with colorectal cancer (CRC) have interval cancers, which develop within six to 60 months of colonoscopy.
Presence of a particular biotype of the Streptococcus bovis bacterium can be an indicator of a GI malignancy.
Adenoma detection rate is inversely associated with risk of interval colorectal cancer
Richard M. Goldberg, MD, discusses results from a recently published study demonstrating that a stool DNA test may be better than FIT for detecting colorectal cancer.
A new study suggests that a noninvasive DNA stool test may enhance the efficacy of screening for colorectal cancer.
Colonoscopy quality and safety are comparable for nurse and physician endoscopy trainees.
Bowel preparation plays a key role in deciding when to schedule follow-up screening for colorectal cancer.
Caused by chemotherapeutic agents and malignancies alike, neutropenic enterocolitis is a side effect that can lead to significant patient morbidity.
Obese individuals have increased odds of having three or more polyps and tubular adenomas.
Fecal immunochemical tests have moderate sensitivity, high specificity, and high overall diagnostic accuracy for detecting CRC.
In two studies, endoscopy and fecal occult-blood testing show lasting reductions in CRC mortality.
Follow-up care for CRC should be performed based on presumed risk of recurrence and patients' functional status.
For people with a family history of colorectal adenomas and advanced adenomas, the risk of developing colorectal cancer is significantly elevated.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib